Cargando…

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma

Detalles Bibliográficos
Autores principales:	Freeman, Morganna, Weber, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645230/ http://dx.doi.org/10.1186/2051-1426-3-S2-P133

Ejemplares similares

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
por: Le, Dung T, et al.
Publicado: (2015)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
por: Weber, Jeffrey, et al.
Publicado: (2015)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent
por: Sharma, Padmanee, et al.
Publicado: (2015)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
por: Pinto, Rosamaria, et al.
Publicado: (2015)

Metabolic mechanisms regulating distinct steps of the melanoma metastatic cascade
por: Piskounova, Elena, et al.
Publicado: (2014)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Diversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma
por: Crystal, Jessica S, et al.
Publicado: (2015)

Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis
por: Almohideb, Mohammad
Publicado: (2022)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Juvenile polymyositis and leptospirosis association: case report
por: Paim-Marques, Luciana B, et al.
Publicado: (2014)

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
por: Dillman, Robert O, et al.
Publicado: (2015)

The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
por: Jin, Conghui, et al.
Publicado: (2016)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma
por: Aedo-Lopez, Veronica, et al.
Publicado: (2022)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship
por: Freeman, Morganna, et al.
Publicado: (2019)

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
por: Vitale, Maria Giuseppa, et al.
Publicado: (2018)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Analysis of B cell subsets in severe cutaneous adverse reaction
por: Azukizawa, Hiroaki, et al.
Publicado: (2014)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis
por: Zarychanski, R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6g2dtbsofh0lie1mfi5fd52k0t